These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 39053193)

  • 1. Development of narrow-spectrum topoisomerase-targeting antibacterials against mycobacteria.
    Sterle M; Habjan E; Piga M; Peršolja P; Durcik M; Dernovšek J; Szili P; Czikkely MS; Zidar N; Janez I; Pal C; Accetto T; Pardo LA; Kikelj D; Peterlin Mašič L; Tomašič T; Bitter W; Cotman AE; Speer A; Zega A
    Eur J Med Chem; 2024 Oct; 276():116693. PubMed ID: 39053193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and antitubercular activity of 4-alkoxy-triazoloquinolones able to inhibit the M. tuberculosis DNA gyrase.
    Carta A; Bua A; Corona P; Piras S; Briguglio I; Molicotti P; Zanetti S; Laurini E; Aulic S; Fermeglia M; Pricl S
    Eur J Med Chem; 2019 Jan; 161():399-415. PubMed ID: 30384044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Mycobacterium tuberculosis NBTI DNA Gyrase Inhibitor Is Active against Mycobacterium abscessus.
    Ganapathy US; Del Río RG; Cacho-Izquierdo M; Ortega F; Lelièvre J; Barros-Aguirre D; Aragaw WW; Zimmerman MD; Lindman M; Dartois V; Gengenbacher M; Dick T
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0151421. PubMed ID: 34606340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis.
    Renuka J; Reddy KI; Srihari K; Jeankumar VU; Shravan M; Sridevi JP; Yogeeswari P; Babu KS; Sriram D
    Bioorg Med Chem; 2014 Sep; 22(17):4924-34. PubMed ID: 25129171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.
    Medapi B; Suryadevara P; Renuka J; Sridevi JP; Yogeeswari P; Sriram D
    Eur J Med Chem; 2015 Oct; 103():1-16. PubMed ID: 26318054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel anti-tubercular and antibacterial based benzosuberone-thiazole moieties: Synthesis, molecular docking analysis, DNA gyrase supercoiling and ATPase activity.
    Omar MA; Masaret GS; Abbas EMH; Abdel-Aziz MM; Harras MF; Farghaly TA
    Bioorg Chem; 2020 Nov; 104():104316. PubMed ID: 33022549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extending the N-linked aminopiperidine class to the mycobacterial gyrase domain: pharmacophore mapping from known antibacterial leads.
    Bobesh KA; Renuka J; Jeankumar VU; Shruti SK; Sridevi JP; Yogeeswari P; Sriram D
    Eur J Med Chem; 2014 Oct; 85():593-604. PubMed ID: 25127151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based drug repurposing to inhibit the DNA gyrase of Mycobacterium tuberculosis.
    Gl B; Rajput R; Gupta M; Dahiya P; Thakur JK; Bhatnagar R; Grover A
    Biochem J; 2020 Nov; 477(21):4167-4190. PubMed ID: 33030198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thiazole-aminopiperidine hybrid analogues: design and synthesis of novel Mycobacterium tuberculosis GyrB inhibitors.
    Jeankumar VU; Renuka J; Santosh P; Soni V; Sridevi JP; Suryadevara P; Yogeeswari P; Sriram D
    Eur J Med Chem; 2013; 70():143-53. PubMed ID: 24148991
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Aragaw WW; Cotroneo N; Stokes S; Pucci M; Critchley I; Gengenbacher M; Dick T
    Microbiol Spectr; 2022 Feb; 10(1):e0132121. PubMed ID: 35019671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An efficient synthesis and biological screening of benzofuran and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis DNA GyrB inhibition.
    Reddy KI; Srihari K; Renuka J; Sree KS; Chuppala A; Jeankumar VU; Sridevi JP; Babu KS; Yogeeswari P; Sriram D
    Bioorg Med Chem; 2014 Dec; 22(23):6552-6563. PubMed ID: 25456076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for Inhibition of Topoisomerase 1A by Gold(III) Macrocycles and Chelates Targeting Mycobacterium tuberculosis and Mycobacterium abscessus.
    Gupta R; Rodrigues Felix C; Akerman MP; Akerman KJ; Slabber CA; Wang W; Adams J; Shaw LN; Tse-Dinh YC; Munro OQ; Rohde KH
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29483110
    [No Abstract]   [Full Text] [Related]  

  • 13. Benzothiazinone-piperazine derivatives as efficient Mycobacterium tuberculosis DNA gyrase inhibitors.
    Chandran M; Renuka J; Sridevi JP; Pedgaonkar GS; Asmitha V; Yogeeswari P; Sriram D
    Int J Mycobacteriol; 2015 Jun; 4(2):104-15. PubMed ID: 26972878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ligand-Based Virtual Screening for Discovery of Indole Derivatives as Potent DNA Gyrase ATPase Inhibitors Active against
    Pakamwong B; Thongdee P; Kamsri B; Phusi N; Taveepanich S; Chayajarus K; Kamsri P; Punkvang A; Hannongbua S; Sangswan J; Suttisintong K; Sureram S; Kittakoop P; Hongmanee P; Santanirand P; Leanpolchareanchai J; Spencer J; Mulholland AJ; Pungpo P
    J Chem Inf Model; 2024 Aug; 64(15):5991-6002. PubMed ID: 38993154
    [No Abstract]   [Full Text] [Related]  

  • 15. Design and synthesis of novel quinoline-aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNA gyraseB inhibitors.
    Medapi B; Renuka J; Saxena S; Sridevi JP; Medishetti R; Kulkarni P; Yogeeswari P; Sriram D
    Bioorg Med Chem; 2015 May; 23(9):2062-78. PubMed ID: 25801151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel 1,2,4-oxadiazole-chalcone/oxime hybrids as potential antibacterial DNA gyrase inhibitors: Design, synthesis, ADMET prediction and molecular docking study.
    Ibrahim TS; Almalki AJ; Moustafa AH; Allam RM; Abuo-Rahma GEA; El Subbagh HI; Mohamed MFA
    Bioorg Chem; 2021 Jun; 111():104885. PubMed ID: 33838559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and antibacterial evaluation of new quinoline-1,3,4-oxadiazole and quinoline-1,2,4-triazole hybrids as potential inhibitors of DNA gyrase and topoisomerase IV.
    Hofny HA; Mohamed MFA; Gomaa HAM; Abdel-Aziz SA; Youssif BGM; El-Koussi NA; Aboraia AS
    Bioorg Chem; 2021 Jul; 112():104920. PubMed ID: 33910078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New N-phenylpyrrolamide DNA gyrase B inhibitors: Optimization of efficacy and antibacterial activity.
    Durcik M; Lovison D; Skok Ž; Durante Cruz C; Tammela P; Tomašič T; Benedetto Tiz D; Draskovits G; Nyerges Á; Pál C; Ilaš J; Peterlin Mašič L; Kikelj D; Zidar N
    Eur J Med Chem; 2018 Jun; 154():117-132. PubMed ID: 29778894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and antibacterial properties of pyrimido[4,5-b]indol-8-amine inhibitors of DNA gyrase.
    McGarry DH; Cooper IR; Walker R; Warrilow CE; Pichowicz M; Ratcliffe AJ; Salisbury AM; Savage VJ; Moyo E; Maclean J; Smith A; Charrier C; Stokes NR; Lindsay DM; Kerr WJ
    Bioorg Med Chem Lett; 2018 Sep; 28(17):2998-3003. PubMed ID: 30122228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Potent DNA Gyrase Inhibitors Active against
    Pakamwong B; Thongdee P; Kamsri B; Phusi N; Kamsri P; Punkvang A; Ketrat S; Saparpakorn P; Hannongbua S; Ariyachaokun K; Suttisintong K; Sureram S; Kittakoop P; Hongmanee P; Santanirand P; Spencer J; Mulholland AJ; Pungpo P
    J Chem Inf Model; 2022 Apr; 62(7):1680-1690. PubMed ID: 35347987
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.